ImmVirX receives $858,183 R&D tax refund
Melbourne, Australia 4 March 2022 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, today announced that it has received a $858,183 Research and Development (R&D) tax refund as part of the […]
ImmVirX extends Research Services Agreement with University of Newcastle & HMRI through to 2024
Melbourne, Australia 6 December 2021 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, today announced the option to extend its relationship with the University of Newcastle through to December 2024. Under the ongoing Research Services […]
ImmVirX closes upsized $25m Series A financing
Melbourne, Australia 8 November 2021 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, today announced the successful upsizing and completion of its $25m Series A financing. The initial tranche of $22m […]
ImmVirX Announces $22 Million Series A Financing
Proceeds to accelerate development of receptor targeted oncolytic RNA viruses Clinical studies of lead candidate IVX 037 expected Q1 2022 Melbourne, Australia 14th May 2021 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and […]
